Description

Activity of GFR/PI3K/AKT pathway inhibitors in glioblastoma clinical trials has not been robust. We hypothesized variations in the pathway between tumors contribute to poor response. We clustered GBM based on

Activity of GFR/PI3K/AKT pathway inhibitors in glioblastoma clinical trials has not been robust. We hypothesized variations in the pathway between tumors contribute to poor response. We clustered GBM based on AKT pathway genes and discovered new subtypes then characterized their clinical and molecular features. There are at least 5 GBM AKT subtypes having distinct DNA copy number alterations, enrichment in oncogenes and tumor suppressor genes and patterns of expression for PI3K/AKT/mTOR signaling components.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2014-07-01
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1371/journal.pone.0100827
    • Identifier Type
      International standard serial number
      Identifier Value
      1045-3830
    • Identifier Type
      International standard serial number
      Identifier Value
      1939-1560

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Joy, A., Ramesh, A., Smirnov, I., Reiser, M., Misra, A., Shapiro, W. R., . . . Feuerstein, B. G. (2014). AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma. PLoS ONE, 9(7). doi:10.1371/journal.pone.0100827

    Machine-readable links